Nutritional and Metabolic Diseases

Gland and Hormone Related Diseases

All Conditions

Neoplasms

Digestive System Diseases

Rare Diseases

Diabetes Mellitus

Pancreatic Neoplasms

Endocrine System Diseases

Metabolic Diseases

Glucose Metabolism Disorders

Pancreatic Cancer

Hypoglycemic Agents

All Drugs and Chemicals

Metformin

Insulin

Insulin, Globin Zinc

1. For patients with new-onset diabetes Fasting blood glucose 7-10 mmol/L, metformin 2 g/day, BID, PO; Fasting blood glucose 10-14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 12 U before breakfast, 8 U; Fasting blood glucose \> 14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 16 U before breakfast, 10 U; Adjusting insulin dosage according to the monitor of fasting blood glucose.
2. For patients with history of diabetes Adjusting metformin or insulin dosage according to the monitor of fasting blood glucose.

Metformin or insulin treatment

Guopei Luo, M.D., Ph.D.

About 80% of patients with pancreatic adenocarcinoma have aberrant fasting blood glucose at the time of diagnosis. The consistent association between pancreatic cancer and diabetes mellitus has long been recognized and even been termed as "chicken and egg". Many reports have found that pancreatic cancer can result in diabetes, which is called type 3c diabetes. New-onset diabetes is commonly observed in pancreatic cancer patients and has been considered as a potential screening sign. Moreover, diabetes has been found as a predictor of poor outcome in pancreatic cancer.

Pancreatic cancer cells have a strong dependence on glucose and they are well-known for their sweet teeth. High glucose is associated with impaired immunologic reaction, intolerability to chemotherapy, radiotherapy and other major treatments, an increased risk of pancreatic surgery. Given the linkage between pancreatic cancer and diabetes or high blood glucose, a clinical trial is needed to validate the effect of metformin and insulin on regulating blood glucose in type 3c diabetes.

Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)

Administration of Metformin and Insulin to Pancreatic Cancer Related Diabetes Mellitus (Type 3c)

Change of tumor biomarkers before and after anti-diabetic administration.Patients will collect CA19-9 values on the day of enrollment and on day 8.

OS of subjects from recruiting to the time of death from any cause

Blood glucose control rate before and after anti-diabetic administration

HbA1C control rate before and after anti-diabetic administration

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)	NCT05306028	Pancretic Cance... Diabete Mellitu...	Metformin or in...	18 Years - 80 Years	Fudan University
Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)	NCT05306028	Pancretic Cance... Diabete Mellitu...	Metformin or in...	18 Years - 80 Years	Fudan University

Spots Global Cancer Trial Database for pancretic cancer